Cormac Sheridan. Show Affiliations »
Abstract
Entities: Disease
Mesh： See more » Antibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/economicsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedDrug ApprovalDrug Industry/economicsDrug Industry/trendsDrug-Related Side Effects and Adverse ReactionsEuropean UnionHumansLeukoencephalopathy, Progressive Multifocal/chemically inducedLeukoencephalopathy, Progressive Multifocal/prevention & controlMarketing/economicsMarketing/trendsMultiple Sclerosis/drug therapyNatalizumabRisk AssessmentRisk FactorsUnited States
Substances： See more » Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedNatalizumab
Year: 2006 PMID： 16900111 DOI： 10.1038/nbt0806-874
Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908